Table S1. Characteristics of included studies of STAT4 rs7574865 and autoimmune diseases

Study
Authors, year [reference] / Subgroup / Ethnicity / Disease / Sample size
Case/Control / MAF
Case / Control / Major findings
OR (95%CI) / Powera / HWEb
P value
Abelson et al.2008 [234] / Spanish / European / SLE / 375/472 / 0.310/0.220 / 1.64 (1.31-2.03) / 0.829 / 0.227
Germany / European / SLE / 247/220 / 0.265/0.210 / 1.37 (1.01-1.85) / 0.582 / 0.945
Italy / European / SLE / 221/207 / 0.394/0.193 / 2.71 (1.99-3.70) / 0.547 / 0.904
Argentina / South American / SLE / 171/171 / 0.415/0.319 / 1.52 (1.11-2.07) / 0.459 / 0.896
Mexico / North American / SLE / 231/250 / 0.547/0.364 / 2.11 (1.63-2.74) / 0.596 / 0.973
SLEGEN 2008 [259] / European / SLE / 720/2337 / 0.316/0.235 / 1.50 (1.24-1.82) / 0.997 / 0.976
Kawasaki et al.2008 [260] / Asian / SLE / 308/306 / 0.463/0.335 / 1.71 (1.36-2.15) / 0.703 / 0.549
Kiyohara et al.2009 [261] / Asian / SLE / 152/427 / 0.375/0.290 / 1.54 (1.06-2.24) / 0.571 / 0.640
Kobayashi et al.2008 [121] / TWMA / Asian / SLE / 227/745 / 0.438/0.311 / 1.73 (1.38-2.15) / 0.759 / 0.765
RIKEN / Asian / SLE / 183/938 / 0.385/0.310 / 1.40 (1.10-1.77) / 0.707 / 0.357
Tokushima/Fukuoka / Asian / SLE / 165/212 / 0.439/0.284 / 1.79 (1.31-2.45) / 0.491 / 0.840
IORRA / Asian / RA / 1481/745 / 0.369/0.311 / 1.29 (1.13-1.48) / 0.994 / 0.765
RIKEN / Asian / RA / 1109/938 / 0.371/0.310 / 1.31 (1.15-1.50) / 0.995 / 0.357
Tukushima / Asian / RA / 941/500 / 0.374/0.338 / 1.17 (0.99-1.38) / 0.953 / 0.533
Palomino-Morales et al.2008 [219] / South American / SLE / 144/410 / 0.427/0.315 / 1.62 (1.22-2.16) / 0.550 / 0.215
South American / RA / 257/410 / 0.385/0.315 / 1.36 (1.08-1.71) / 0.717 / 0.215
Remmers et al.2007 [119] / UCSF / European / SLE / 575/416 / 0.310/0.220 / 1.61 (1.30-1.99) / 0.878 / 0.971
ABcoN / European / SLE / 349/416 / 0.310/0.230 / 1.52 (1.20-1.91) / 0.792 / 0.983
MADGC / European / SLE / 115/416 / 0.291/0.220 / 1.46 (1.03-2.06) / 0.485 / 0.971
NARAC / European / RA / 607/1309 / 0.280/0.220 / 1.37 (1.17-1.60) / 0.984 / 0.975
Replication series / European / RA / 1013/1326 / 0.260/0.220 / 1.28 (1.11-1.47) / 0.998 / 0.990
EIRA / European / RA / 1529/881 / 0.250/0.220 / 1.18 (1.02-1.36) / 0.998 / 0.956
Suarez-Gestal (1) et al.2009 [263] / Czech Republic / European / SLE / 101/99 / 0.342/0.263 / 1.46 (0.95-2.24) / 0.294 / 0.343
Suarez-Gestal (1) et al.2009 [263] / Greece-1 / European / SLE / 94/99 / 0.388/0.278 / 1.47 (0.96-2.25) / 0.285 / 0.412
Greece-2 / European / SLE / 94/88 / 0.346/0.222 / 2.23 (1.41-3.54) / 0.284 / 0.675
Hungary / European / SLE / 95/95 / 0.289/0.205 / 1.58 (0.98-2.53) / 0.282 / 0.208
Milan / European / SLE / 128/106 / 0.328/0.226 / 1.67 (1.10-2.53) / 0.332 / 0.754
Portugal / European / SLE / 94/95 / 0.346/0.242 / 1.65 (1.06-2.59) / 0.281 / 0.151
Madrid / European / SLE / 92/98 / 0.326/0.209 / 1.83 (1.15-2.90) / 0.282 / 0.296
Santiago / European / SLE / 109/95 / 0.284/0.211 / 1.49 (0.94-2.35) / 0.298 / 0.867
Coruña / European / SLE / 88/81 / 0.278/0.213 / 1.42 (0.86-2.34) / 0.255 / 0.861
Barcelona / European / SLE / 89/96 / 0.320/0.260 / 1.34 (0.85-2.10) / 0.276 / 0.787
Slovakia / European / SLE / 94/93 / 0.346/0.215 / 1.93 (1.22-3.06) / 0.278 / 0.668
Yang et al.2009 [258] / HK / Asian / SLE / 910/1440 / 0.461/0.334 / 1.70 (1.51-1.92) / 0.997 / 0.969
Thai / Asian / SLE / 278/383 / 0.487/0.352 / 1.75 (1.40-2.19) / 0.725 / 0.926
Han et al.2009 [262] / GWAS / Asian / SLE / 1047/1205 / 0.419/0.325 / 1.53 (1.33-1.69) / 0.998 / 0.979
Replication 1 / Asian / SLE / 1643/5930 / 0.415/0.325 / 1.47 (1.36-1.60) / 1.000 / 0.994
Replication 2 / Asian / SLE / 1509/1120 / 0.433/0.345 / 1.46 (1.31-1.64) / 0.999 / 1.000
Li et al.2010[] / Asian / SLE / 748/744 / 0.410/0.322 / 1.46 (1.26-1.70) / 0.973 / 0.233
Barton et al.2008 [214] / WTCCC / European / RA / 1858/2934 / 0.237/0.219 / 1.11 (1.00-1.22) / 1.000 / 0.564
validation study / European / RA / 3399/3024 / 0.244/0.216 / 1.17 (1.08-1.28) / 1.000 / 0.951
Lee et al.2007 [120] / Asian / RA / 1032/908 / 0.385/0.331 / 1.29 (1.07-1.54) / 0.993 / 0.505
Martinez et al.2008 [124] / European / RA / 559/716 / 0.271/0.194 / 1.59 (1.31-1.92) / 0.946 / 0.968
European / T1D / 311/716 / 0.241/0.194 / 1.36 (1.07-1.71) / 0.844 / 0.968
European / IBD / 674/716 / 0.232/0.190 / 1.29 (1.07-1.55) / 0.964 / 0.968
European / IBD-CD / 322/716 / 0.233/0.194 / 1.30 (1.02-1.67) / 0.852 / 0.968
European / IBD-UC / 352/716 / 0.232/0.194 / 1.29 (1.02-1.64) / 0.872 / 0.968
European / MS / 426/716 / 0.190/0.194 / 1.02 (0.82-1.28) / 0.909 / 0.968
Orozco et al.2009 [217] / Spanish / European / RA / 923/1296 / 0.248/0.208 / 1.26 (1.09-1.45) / 0.997 / 0.888
Orozco et al.2009 [217] / Dutch / European / RA / 876/893 / 0.241/0.217 / 1.35 (1.03-1.77) / 0.989 / 0.422
Swedish / European / RA / 273/285 / 0.289/0.232 / 1.45 (1.21-1.73) / 0.661 / 0.812
Suarez-Gestal (2) et al.2009 [220] / European / RA / 1348/1806 / 0.240/0.217 / 1.14 (1.01-1.28) / 1.000 / 0.991
Daha et al.2009 [215] / European / RA / 854/866 / 0.253/0.222 / 1.19 (1.01-1.40) / 0.987 / 0.985
Kelley et al.2010 [216] / African American / RA / 723/660 / 0.149/0.133 / 1.22 (0.91-1.63) / 0.963 / 0.928
Liang et al.2011[] / Asian / RA / 208/312 / 0.428/0.312 / 1.65 (1.27-2.13) / 0.614 / 0.361
Ben hamad et al.2011[] / African / RA / 140/200 / 0.250/0.168 / 1.66 (1.14-2.42) / 0.447 / 0.067
African / AITD / 159/200 / 0.200/0.168 / 1.25 (0.86-1.83) / 0.483 / 0.067
Fung et al.2009 [264] / European / T1D / 8010/9733 / 0.240/0.220 / 1.10 (1.04-1.15) / 1.000 / 0.991
Lee et al.2008 [265] / Asian / T1D / 389/152 / 0.337/0.313 / 1.17 (0.84-1.49) / 0.554 / 0.953
Gourh et al.2009 [266] / SSc Registry / European / SSc / 880/507 / 0.260/0.210 / 1.32 (1.10-1.60) / 0.951 / 0.921
UT Division / European / SSc / 522/531 / 0.280/0.250 / 1.17 (0.96-1.42) / 0.904 / 0.988
Tsuchiya et al.2009 [267] / Asian / SSc / 282/590 / 0.410/0.340 / 1.35 (1.10-1.65) / 0.795 / 0.695
Dieude et al.2009 [130] / Discovery set / European / SSc / 402/481 / 0.271/0.229 / 1.26 91.12-1.56) / 0.846 / 0.183
Replication set / European / SSc / 399/483 / 0.266/0.213 / 1.35 (1.07-1.66) / 0.845 / 0.992
Rueda et al.2009 [128] / Spanish / European / SSc / 332/1296 / 0.279/0.208 / 1.48 (1.21-1.79) / 0.907 / 0.888
Dutch / European / SSc / 131/893 / 0.309/0.217 / 1.62 (1.21-2.15) / 0.582 / 0.422
Germany / European / SSc / 270/227 / 0.261/0.220 / 1.45 (1.09-1.94) / 0.607 / 0.996
North-American / North American / SSc / 83/77 / 0.355/0.253 / 1.63 (1.00-2.63) / 0.244 / 0.522
Italian / European / SSc / 351/362 / 0.268/0.211 / 1.36 (1.07-1.74) / 0.766 / 0.318
Swedish / European / SSc / 150/285 / 0.670/0.232 / 1.21 (0.88-1.66) / 0.516 / 0.812
Diaz-Gallo et al.2010 [127] / European / IBD / 900/1296 / 0.208/0.207 / 1.00 (0.86-1.16) / 0.996 / 0.888
European / IBD-CD / 498/1296 / 0.190/0.208 / 0.90 (0.75-1.08) / 0.969 / 0.888
European / IBD-UC / 402/1296 / 0.230/0.198 / 1.14 (0.95-1.38) / 0.942 / 0.888
Glas et al.2010 [125] / European / IBD / 1321/1383 / 0.198/0.215 / 0.90 (0.79-1.03) / 0.999 / 0.999
European / IBD-CD / 857/1383 / 0.190/0.215 / 0.86 (0.74-0.99) / 0.996 / 0.999
Glas et al.2010 [125] / European / IBD-UC / 464/1383 / 0.214/0.215 / 1.00 (0.83-1.20) / 0.964 / 0.999
Moon et al.2010 [122] / Asian / IBD / 428/229 / 0.324/0.319 / 1.02 (0.80-1.30) / 0.689 / 0.934
Asian / IBD-CD / 182/229 / 0.302/0.319 / 0.93 (0.69-1.25) / 0.527 / 0.934
Asian / IBD-UC / 246/229 / 0.339/0.319 / 1.10 (0.84-1.44) / 0.591 / 0.934
Hinks et al.2009 [269] / European / JIA / 1054/3531 / 0.260/0.220 / 1.24 (1.10-1.39) / 1.000 / 0.602
Prahalad et al.2009 [270] / European / JIA / 443/641 / 0.281/0.237 / 1.24 (1.02-1.51) / 0.904 / 1.000
Thompson et al.2010 / Initial set / European / JIA / 780/3418 / 0.249/0.218 / 1.36 (1.15-1.60) / 0.999 / 0.968
Replication set / European / JIA / 946/1240 / 0.275/0.221 / 1.33 (1.16-1.53) / 0.997 / 0.969
Korman et al.2008 [] / European / pSS / 120/1112 / 0.296/0.223 / 1.46 (1.09-1.97) / 0.561 / 0.851
Palomino-Morales et al.2010 [126] / Colombia / European / pSS / 69/296 / 0.341/0.294 / 1.24 (0.82-1.87) / 0.325 / 0.215
Germany / European / pSS / 108/227 / 0.281/0.220 / 1.40 (0.96-2.02) / 0.408 / 0.996
Yin et al.2009 [123] / European / APS / 121/414 / 0.364/0.207 / 2.19 (1.60-2.99) / 0.499 / 0.193
Horita et al.2009 [271] / Asian / APS / 37/414 / 0.486/0.316 / 2.05 (1.27-3.30) / 0.224 / 0.975
Zervou et al.2009 / European / Ps / 163/341 / 0.230/0.179 / 1.42 (1.01-2.00) / 0.563 / 0.070
Wieczorek et al. [116] / European / WG / 612/880 / 0.222/0.221 / 1.01 (0.85-1.20) / 0.969 / 0.998
Palomino-Morales et al.2009 [271] / European / GCA / 201/357 / 0.206/0.178 / 1.12 (0.89-1.64) / 0.628 / 0.328
Howson et al.2011[ ] / European / T2D / 590/938 / 0.250/0.210 / 1.23 (1.09-1.39) / 0.970 / 0.935

MAF: Minor allele frequency; OR: Odds Ratio; 95%CI: 95% Confidence Interval; OA: osteoarthritis; SLE, Systemic lupus erythematosus; RA, Rheumatoid arthritis; T1D, Type 1 diabetes; T2D, Type 2 diabetes; IBD, Inflammatory bowel disease; CD, Crohn’s disease; UC, ulcerative colitis.; SSc, Sysemetic Sclerosis; pSS, Primary Sjogren’s syndrome.; JIA, Juvenile idiopathic arthritis; APS, Primary antiphospholipid syndrome; AITD, Autoimmune thyroid diseases; Ps, Psoriasis; WG, Wegener's granulomatosis; GCA, giant cell arteritis.;Powera calculations assume a=0.05 and minor allele frequencies of 40%, OR=1.5; HWEb: Hardy-Weinberg P value in controls.